ENABLE LIFE SCIENCES LLC

Farmington, CT · Biotech · Private

Cancer-specific monoclonal antibodies combined with adoptive Natural Killer (NK) cell immunotherapy for personalized cancer treatment

Grants
$499K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A Novel Serum Alternative for Ex-vivo Expansion of Natural Killer Cells for Immunotherapy$224,000
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Antibody Therapy that Targets Neoantigens in Acute Myeloid Leukemia via the Antibody Dependent Cell-mediated Cytotoxicity Mechanism of Natural Killer Cells$274,975
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2177PARTILLION BIOSCIENCE CORPORATION——
2178AVADIM HEALTH, INC.—$81M
2179ID4PHARMA, LLC——
2180ENABLE LIFE SCIENCES LLC——
2181General Counsel AI, Inc.—$63M
2182GIWOTECH INC.——
2183City Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Process For Producing Personalized Cancer Immunotherapyapplication
  • Process For Producing Personalized Cancer Immunotherapyapplication
  • Cell Culture Medium For Natural Killer (nk) Cellsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.